Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity

CD8 T 细胞中 Zbtb44-Eomes 复合物的调节和抗肿瘤免疫

基本信息

  • 批准号:
    10574602
  • 负责人:
  • 金额:
    $ 41.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-24 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

ABSTRACT CAR-T cell therapy is an emerging option for cancer treatment, but its efficacy is limited, especially in solid tumors because the effector CD8+T cells become dysfunctional and exhausted in the tumor microenvironment (TME). However, the key pathways that define the delicate balance between the effector vs exhausted state of CD8+T cells remain unclear. Our preliminary studies demonstrate that sumoylation of the T-box transcription factor, Eomesodermin (Eomes), facilitates its association with Zbtb44, a member of the ThPOK family of transcription factors. The Zbtb44-Eomes complex promotes the effector function and anti-tumor activity of CD8+ tumor infiltrated lymphocytes (TILs). In exhausted CD8+ TILs, the ubiquitin ligase Trim47 targets Zbtb44 for degradation and disrupts the Zbtb44-Eomes complex. Furthermore, CRISPR-Cas9-mediated inhibition of Trim47 rescues exhausted CD8+ TILs and restores their effector function. These preliminary findings led us to hypothesize that ubiquitination and sumoylation of the Zbtb44/Eomes complex are critical molecular events that dictate the effector vs exhaustion of CD8+ TILs which can be therapeutically targeted. In Aim1, we will determine the mechanism by which the Zbtb44-Eomes complex promotes effector CD8+T cell function and anti-tumor immunity. We will use newly generated Zbtb44-/- mice to investigate how sumoylation of Eomes at Lys(K)-446 facilitates the formation of the Zbtb44-Eomes complex via the SUMO interacting motif (SIM) within Zbtb44. Further, we will delineate the mechanism by which the Zbtb44-Eomes complex cooperatively binds to and transactivates the IFN- promoter. In Aim 2, we will determine the mechanism by which Trim47-mediated ubiquitination of Zbtb44 leads to dysfunction of CD8+T cells. We will investigate how Trim47, which is upregulated in exhausted (PD1+Tim3+) CD8+ TILs, targets Zbtb44 for ubiquitination at K139 and promotes its degradation. Using newly generated Trim47-/- mice, we will determine how disruption of the Zbtb44- Eomes complex leads to the inhibitory transcriptional profile of exhausted CD8+T cells. In Aim 3, we will target the Zbtb44-Trim47 pathway to promote anti-tumor immunity. We will test the therapeutic potential of blocking Zbtb44 ubiquitination in CAR-T cells against carcinoembryonic antigen (CEA) in the MC38 and in a patient- derived xenograft (PDX) colon cancer model. Completion of these studies will lead to: 1) dissection of the novel Zbtb44-Eomes complex that is critical for effector CD8+ T cell function, 2) determination of how Trim47-mediated ubiquitination disrupts this complex leading to alternate transcription profile in exhausted CD8+ TILs, and 3) evaluate the means to target the Zbtb44- Trim47 pathway to overcome the current limitations of CAR-T cell therapy for solid tumors.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Venuprasad K Poojary其他文献

Venuprasad K Poojary的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Venuprasad K Poojary', 18)}}的其他基金

Znf740 in the regulation of CD8+T cell exhaustion
Znf740 调节 CD8 T 细胞耗竭
  • 批准号:
    10715852
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of RORγt in Th17-mediated inflammation
RORγt 在 Th17 介导的炎症中的调节
  • 批准号:
    10509373
  • 财政年份:
    2022
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of RORγt in Th17-mediated inflammation
RORγt 在 Th17 介导的炎症中的调节
  • 批准号:
    10646293
  • 财政年份:
    2022
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of CD8+T cells by Zbtb42
Zbtb42 对 CD8 T 细胞的调节
  • 批准号:
    10661809
  • 财政年份:
    2022
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
CD8 T 细胞中 Zbtb44-Eomes 复合物的调节和抗肿瘤免疫
  • 批准号:
    10377321
  • 财政年份:
    2021
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of ROR-gt in colonic inflammation
ROR-gt 在结肠炎症中的调节
  • 批准号:
    9886237
  • 财政年份:
    2018
  • 资助金额:
    $ 41.01万
  • 项目类别:
Regulation of ROR-gt in colonic inflammation
ROR-gt 在结肠炎症中的调节
  • 批准号:
    10113592
  • 财政年份:
    2018
  • 资助金额:
    $ 41.01万
  • 项目类别:
Role of TIEG1 in Foxp3+Treg development and tumor progression
TIEG1 在 Foxp3 Treg 发育和肿瘤进展中的作用
  • 批准号:
    7830845
  • 财政年份:
    2009
  • 资助金额:
    $ 41.01万
  • 项目类别:
Role of TIEG1 in Foxp3+Treg development and tumor progression
TIEG1 在 Foxp3 Treg 发育和肿瘤进展中的作用
  • 批准号:
    7943954
  • 财政年份:
    2009
  • 资助金额:
    $ 41.01万
  • 项目类别:

相似海外基金

Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 41.01万
  • 项目类别:
Improving Chimeric Antigen Receptor (CAR) T-Cell Therapy Using Engineering Biology and Mechanobiological Approach
利用工程生物学和力学生物学方法改进嵌合抗原受体 (CAR) T 细胞疗法
  • 批准号:
    10074571
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
    Grant for R&D
Democratizing CAR T cell therapy by in situ programming of virus-specific T cells
通过病毒特异性 T 细胞的原位编程使 CAR T 细胞疗法大众化
  • 批准号:
    10739646
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
High throughput genetics to enhance long-term efficacy and function of CAR-T cell therapy in solid cancers
高通量遗传学可增强 CAR-T 细胞疗法在实体癌中的长期疗效和功能
  • 批准号:
    2895113
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
    Studentship
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
CD19 靶向 CAR-T 细胞治疗后的免疫球蛋白替代疗法和感染并发症
  • 批准号:
    10732195
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
Programming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy.
使用 IL-13Ra2/TGF-b CAR-T 细胞疗法对胶质母细胞瘤进行多管齐下的免疫反应。
  • 批准号:
    10586951
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed
一种新型 CAR-T 细胞疗法,用于一次性治疗未接受 ART 抑制的慢性 HIV 感染患者
  • 批准号:
    10739333
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
Creation of a CAR-T cell therapy RNA vaccine that blocks the progression of tumors with strong stromal reactions
开发 CAR-T 细胞疗法 RNA 疫苗,通过强烈的基质反应阻止肿瘤的进展
  • 批准号:
    23K19505
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Overcoming the Limitations in CAR-T Cell Therapy: Development of a Novel, Off-the-shelf Antibody-Cell Complex
克服 CAR-T 细胞疗法的局限性:开发新型现成抗体细胞复合物
  • 批准号:
    23K17433
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Pioneering)
Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy
CAR-T 细胞治疗后神经毒性和长期结果的脑成像标志物
  • 批准号:
    10657106
  • 财政年份:
    2023
  • 资助金额:
    $ 41.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了